See more : Arcellx, Inc. (ACLX) Income Statement Analysis – Financial Results
Complete financial analysis of BioArctic AB (publ) (BRCTF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BioArctic AB (publ), a leading company in the Biotechnology industry within the Healthcare sector.
- Bleecker Société Anonyme (BLEE.PA) Income Statement Analysis – Financial Results
- KRYSTAL INTEGRATED (KRYSTAL.NS) Income Statement Analysis – Financial Results
- Parrot S.A. (PARRO.PA) Income Statement Analysis – Financial Results
- NIKE, Inc. (NKE.NE) Income Statement Analysis – Financial Results
- Edify Acquisition Corp. (EACPW) Income Statement Analysis – Financial Results
BioArctic AB (publ) (BRCTF)
About BioArctic AB (publ)
BioArctic AB (publ), a research-intensive biopharmaceutical company, develops biological drugs for patients with neurodegenerative disorders in Sweden. The company develops BAN2401, an immunotherapy, which is in Phase III clinical trials targeting the toxic amyloid-beta oligomers/protofibrils in Alzheimer's disease; and is in preclinical trials for treating Down's syndrome with dementia and traumatic brain injury, as well as BAN2401 Back-up, a disease modifying antibody treatment that is in late preclinical Phase for patients with early Alzheimer's disease. It also develops ABBV-0805, a monoclonal antibody for treating Parkinson's disease; and SC0806, a biodegradable device that is in Phase I/II clinical trial for spinal cord injuries. In addition, the company develops imaging and biochemical biomarkers for Alzheimer's and Parkinson's disease; and blood-brain-barrier technology that enables the passage of antibodies and other substances into the brain through the blood brain barrier, as well as focuses on developing ND3014 antibodies for treating neurodegenerative disorders; AD1801, AD1502, AD1503, AD-BT2802, AD-BT2803, and AD2603 for the treatment of Alzheimer's disease; and PD1601 and PD1602 for the treatment of Parkinson's disease. It has research collaboration agreement with Eisai and AbbVie. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was founded in 1992 and is based in Stockholm, Sweden.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 616.00M | 228.29M | 23.15M | 62.35M | 281.77M | 713.97M | 140.71M | 105.61M | 41.57M |
| Cost of Revenue | 89.63M | 74.33M | 55.07M | 50.24M | 72.42M | 145.36M | 63.64M | 238.00K | 0.00 |
| Gross Profit | 526.37M | 153.97M | -31.92M | 12.11M | 209.35M | 568.61M | 77.07M | 105.38M | 41.57M |
| Gross Profit Ratio | 85.45% | 67.44% | -137.91% | 19.42% | 74.30% | 79.64% | 54.77% | 99.77% | 100.00% |
| Research & Development | 0.00 | 7.10M | 6.06M | 6.12M | 7.74M | 16.40M | 101.58M | 53.67M | 38.24M |
| General & Administrative | 0.00 | 0.00 | 24.85M | 23.37M | 31.17M | 31.95M | 31.52M | 14.54M | 4.56M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.40M | 1.37M | 1.45M |
| SG&A | 251.25M | 148.67M | 24.85M | 23.37M | 31.17M | 31.95M | 32.92M | 15.91M | 6.01M |
| Other Expenses | 22.48M | 0.00 | 0.00 | 0.00 | 0.00 | 7.00K | 678.00K | 2.08M | 524.00K |
| Operating Expenses | 273.73M | 161.90M | 107.93M | 94.42M | 98.26M | 82.79M | 53.72M | 44.77M | 37.27M |
| Cost & Expenses | 363.36M | 236.23M | 163.00M | 144.67M | 170.68M | 228.14M | 117.36M | 45.01M | 37.27M |
| Interest Income | 34.23M | 2.54M | 0.00 | 7.00K | 253.00K | 40.00K | 65.00K | 8.00K | 232.00K |
| Interest Expense | 379.00K | 559.00K | 838.00K | 984.00K | 1.19M | 1.37M | 647.00K | 5.00K | 8.00K |
| Depreciation & Amortization | 18.43M | 14.63M | 13.11M | 11.01M | 9.20M | 2.06M | 1.99M | 1.56M | 1.54M |
| EBITDA | 295.24M | 4.03M | -126.57M | -74.69M | 123.37M | 487.89M | 26.02M | 64.24M | 6.36M |
| EBITDA Ratio | 47.93% | 1.76% | -546.78% | -119.47% | 43.78% | 69.05% | 15.42% | 71.67% | 15.26% |
| Operating Income | 252.64M | -17.44M | -139.72M | -85.01M | 112.54M | 488.79M | 19.29M | 74.63M | 4.84M |
| Operating Income Ratio | 41.01% | -7.64% | -603.66% | -136.35% | 39.94% | 68.46% | 13.71% | 70.66% | 11.65% |
| Total Other Income/Expenses | 23.85M | 6.17M | -788.00K | -1.68M | 437.00K | 799.00K | 397.00K | -495.00K | -53.00K |
| Income Before Tax | 276.49M | -11.17M | -140.51M | -86.69M | 112.98M | 489.59M | 19.69M | 74.14M | 4.79M |
| Income Before Tax Ratio | 44.88% | -4.89% | -607.06% | -139.05% | 40.09% | 68.57% | 13.99% | 70.20% | 11.52% |
| Income Tax Expense | 47.24M | 11.00K | -20.72M | -18.17M | 24.51M | 107.99M | 4.53M | 16.56M | 1.08M |
| Net Income | 229.25M | -11.18M | -119.79M | -68.52M | 88.47M | 381.60M | 15.16M | 57.58M | 3.71M |
| Net Income Ratio | 37.22% | -4.90% | -517.54% | -109.90% | 31.40% | 53.45% | 10.77% | 54.52% | 8.92% |
| EPS | 2.59 | -0.13 | -1.36 | -0.78 | 1.00 | 4.33 | 0.22 | 0.65 | 0.04 |
| EPS Diluted | 2.59 | -0.13 | -1.36 | -0.78 | 1.00 | 4.33 | 0.22 | 0.65 | 0.04 |
| Weighted Avg Shares Out | 88.51M | 88.07M | 88.06M | 88.06M | 88.06M | 88.06M | 88.06M | 88.06M | 88.06M |
| Weighted Avg Shares Out (Dil) | 88.49M | 88.07M | 88.06M | 88.06M | 88.06M | 88.06M | 88.06M | 88.06M | 88.06M |
LEQEMBI® Q3 2023 sales published - 0.4 billion yen recorded in the period
Latest analysis of lecanemab's effect on biomarkers as well as new data on subcutaneous dosing presented at the AAIC 2023 Alzheimer conference
Latest data on lecanemab to be presented at Alzheimer's Association International Conference (AAIC) 2023
FDA grants traditional approval for LEQEMBI® (lecanemab-irmb) for the treatment of Alzheimer's disease
Source: https://incomestatements.info
Category: Stock Reports